SCHEMBL4607381

SCHEMBL4607381

Cc1ccc(C2CC(C(=O)NN3CCCCC3)=NN2c2ccc(Cl)cc2Cl)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 15/20 0.60
CNR2 P34972 14/20 0.60
ABCC4 O15439 1/20 0.47
MLNR O43193 1/20 0.47
ABCB11 O95342 1/20 0.47
CHRM2 P08172 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CYP2C9 P11712 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
HRH2 P25021 1/20 0.47
HTR2A P28223 1/20 0.47
AGTR1 P30556 1/20 0.47
CCKAR P32238 1/20 0.47
CCKBR P32239 1/20 0.47
MC4R P32245 1/20 0.47
ABCC1 P33527 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605740 0.92 CNR1 (0.61) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4607369 0.92 CNR1 (0.61) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4606627 0.91 CNR1 (0.62) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4606543 0.90 CNR1 (0.59) CNR1CNR2
SCHEMBL4604251 0.89 CNR1 (0.59) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4604771 0.89 CNR1 (0.58) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4605225 0.87 CNR1 (0.56) CNR1CNR2
SCHEMBL4605758 0.86 CNR1 (0.57) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4605472 0.86 CNR1 (0.55) CNR1CNR2KDM4E
SCHEMBL4607161 0.85 CNR1 (0.58) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP claimed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946777-A1 Substituted pyrazoline for preventing weight gain Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
EP-1946778-A1 Active substance combination for the treatment of diabetes Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
WO-2007009690-A1 HETEROCYCLYL-SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A (ES) 2007-01-25 WO disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed
EP-1743894-A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed